Balanced news tone
News Sentiment
HTFL sentiment intelligence
Heartflow, Inc. Common Stock news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Price is moving more forcefully than the current news tone suggests.
81/100 classification confidence.
directly relevant articles
high-authority source matches
-4.5% over one week, -19.6% over four weeks, trend active, and near fair-value range.
Heartflow, Inc. Common Stock (NASDAQ: HTFL) Stock Price, News & Analysis
Market Reaction
Price moving ahead of tone
Price is moving more forcefully than the current news tone suggests.
Sentiment Mix
Positive, neutral, negative
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
News Tape
Relevant headlines
Heartflow, Inc. Common Stock (NASDAQ: HTFL) Stock Price, News & Analysis
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 16 Jul 2026 17:59
- Source
- Kalkine
Stifel reiterates HeartFlow stock rating after cardiology meeting By Investing.com
- Tone
- Neutral 50/100
- Event
- Analyst action
- Published
- 15 Jul 2026 17:42
- Source
- Investing.com Nigeria
Campbell D. Rogers plans 9,219-share HTFL stock sale on NASDAQ
Campbell D. Rogers has filed a notice to sell 9,219 shares of Heartflow, Inc. (HTFL) common stock on NASDAQ on July 15, 2026. These shares were acquired on the same day through a stock option exercise paid in cash, with a planned sale associated amount of $237,112.68. Rogers also
- Tone
- Neutral 50/100
- Event
- Balance sheet
- Published
- 15 Jul 2026 13:41
- Source
- Stock Titan
Heartflow CEO John Farquhar sells $626,095 in company stock
Heartflow CEO John C.M. Farquhar sold 22,562 shares of the company's common stock for $626,095 on July 10, 2026, at a price of $27.75 per share, which is above the current stock price. This transaction was executed under a Rule 10b5-1 trading plan adopted in September 2025. The s
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 14 Jul 2026 03:10
- Source
- Investing.com
Form 4 Heartflow Inc For: 13 July By Investing.com
This article from Investing.com announces the filing of a Form 4 for Heartflow Inc. on July 13. Form 4 filings typically report insider transactions, such as stock purchases or sales by officers and directors of a company. The brief mention suggests transparency regarding the com
- Tone
- Negative 33/100
- Event
- Market update
- Published
- 14 Jul 2026 02:41
- Source
- Investing.com Nigeria
[Form 4] Heartflow, Inc. Insider Trading Activity
Heartflow, Inc.'s CEO, Farquhar John C.M., reported an open-market sale of 22,562 shares of common stock on July 10, 2026, at $27.75 per share, totaling $626,096. This transaction was conducted under a Rule 10b5-1 trading plan established on September 12, 2025. Following the sale
- Tone
- Negative 38/100
- Event
- Market update
- Published
- 14 Jul 2026 00:41
- Source
- Stock Titan
Teleflex Incorporated (TFX) Stock Analysis: Unpacking a 32.3% Revenue Growth in the Healthcare Sector
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 13 Jul 2026 09:24
- Source
- DirectorsTalk Interviews
HeartFlow Sees Insider Stock Selling
HeartFlow, Inc. (NASDAQ:HTFL) has experienced net insider selling over the past year, with President John Farquhar selling US$291k worth of shares at a price below the current market value. Despite this, insiders still own a significant 6.8% of the company, valued at approximatel
- Tone
- Negative 36/100
- Event
- Market update
- Published
- 12 Jul 2026 17:41
- Source
- Sahm
HeartFlow: A Premium AI Diagnostics Story (NASDAQ:HTFL)
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 12 Jul 2026 03:10
- Source
- Seeking Alpha
HeartFlow's AI platform drives strong growth and market potential, prompting a buy recommendation despite high valuation.
HeartFlow, Inc. receives a buy recommendation due to its AI-enabled platform, which significantly improves coronary artery disease diagnosis and boasts 41% year-over-year revenue growth. Despite a high valuation of 8.4 times forward revenue, the company's expanding product suite,
- Tone
- Positive 75/100
- Event
- Earnings
- Published
- 12 Jul 2026 03:41
- Source
- Pluang
Heartflow (HTFL) director William C. Weldon exercises stock options for 51,369 shares
Heartflow (HTFL) director William C. Weldon exercised stock options to acquire 51,369 shares of Common Stock on July 8, 2026. These transactions involved three separate exercises, each for 17,123 shares at an exercise price of $8.33 per share. Following these exercises, Weldon di
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 10 Jul 2026 21:39
- Source
- Stock Titan
[144] Heartflow, Inc. SEC Filing
Heartflow, Inc. (HTFL) has filed a Rule 144 notice to sell 22,562 common shares related to a stock option exercise from June 25, 2024. The filing also documents four recent sales by John C. M. Farquhar in April-June 2026, totaling 106,586 shares for over $3.2 million. The notice
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 10 Jul 2026 14:12
- Source
- Stock Titan
Form 144 Heartflow For: 10 July By Investing.com
This article from Investing.com is a standard Form 144 filing notification for Heartflow (HTFL) on July 10. It also includes general market updates, such as mixed stock performance, oil price movements, and various financial data points. The article primarily serves as a brief an
- Tone
- Negative 42/100
- Event
- Market update
- Published
- 10 Jul 2026 14:12
- Source
- Investing.com Canada
New Data at SCCT 2026 Reinforce Heartflow Plaque Analysis
Heartflow, Inc. announced new data at the SCCT 2026 Annual Scientific Meeting, reinforcing its AI-powered Heartflow Plaque Analysis as the standard for coronary artery disease management. The company also launched Heartflow Plaque Staging, a new tool integrated into every Heartfl
- Tone
- Positive 94/100
- Event
- Market update
- Published
- 09 Jul 2026 11:39
- Source
- GlobeNewswire
Heartflow says zero-calcium patients still carry hidden plaque
Heartflow (Nasdaq: HTFL) announced new clinical data at SCCT 2026, reinforcing its AI-based Plaque Analysis and newly integrated Plaque Staging tool. Studies involving over 36,000 patients revealed that more than 50% of symptomatic individuals with zero coronary artery calcium (C
- Tone
- Positive 73/100
- Event
- Market update
- Published
- 09 Jul 2026 11:39
- Source
- Stock Titan
Heartflow vs. Omeros: Which Healthcare Innovator Stock Is a Better Buy in 2026?
This article compares Heartflow and Omeros as investment opportunities in 2026. Heartflow, specializing in AI-enabled diagnostic software for heart disease, shows rapid revenue growth but faces potential reimbursement risks and ongoing net losses. Omeros is transitioning to a com
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 08 Jul 2026 22:11
- Source
- The Motley Fool
HTFL - Heartflow Inc Volatility & Greeks
This page provides a detailed overview of Heartflow Inc (HTFL) stock, including its latest trading data, financial metrics, and performance indicators. It covers key statistics like market capitalization, income, sales, EPS, insider and institutional ownership, and various ratios
- Tone
- Negative 38/100
- Event
- Earnings
- Published
- 06 Jul 2026 03:39
- Source
- Finviz
HTFL - Heartflow Inc Options
This article provides detailed financial data and stock performance metrics for Heartflow Inc (HTFL). It includes key figures such as market capitalization, sales, income, various financial ratios, and insider/institutional ownership percentages. The data presented aims to offer
- Tone
- Negative 32/100
- Event
- Market update
- Published
- 04 Jul 2026 16:41
- Source
- Finviz
Heartflow vs. Iovance Biotherapeutics: Which Healthcare Stock Is a Better Buy in 2026?
This article compares Heartflow Inc. and Iovance Biotherapeutics, two healthcare stocks specializing in AI diagnostics and personalized cell therapies, respectively. It evaluates their financial health, market risks, and revenue growth in 2025, noting both companies are currently
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 04 Jul 2026 13:40
- Source
- Market source
HeartFlow, Inc. (HTFL) Receives a New Rating from Freedom Capital Markets
Freedom Capital Markets initiated coverage on HeartFlow, Inc. (HTFL) with a Buy rating and a $37.00 price target. This follows Canaccord Genuity also maintaining a Buy rating with the same price target. HeartFlow reported Q1 revenue of $52.59 million and a GAAP net loss of $27.38
- Tone
- Neutral 50/100
- Event
- Analyst action
- Published
- 02 Jul 2026 02:10
- Source
- The Globe and Mail
Heartflow (HTFL) Sees Significant Drop in Stock Price
HeartFlow Inc. (HTFL) experienced a significant 17% stock price drop on June 30, 2026, falling to $28.93, influenced by financial challenges and substantial insider selling totaling $64 million. The company, a medical technology firm specializing in AI solutions for coronary arte
- Tone
- Negative 9/100
- Event
- Market update
- Published
- 30 Jun 2026 17:09
- Source
- GuruFocus
CCORF Maintains Heartflow(HTFL.US) With Buy Rating, Maintains Target Price $37
CCORF has reiterated its Buy rating on Heartflow (HTFL.US), maintaining a target price of $37. This continued positive outlook suggests the firm believes in the company's strong future performance and potential for stock appreciation.
- Tone
- Positive 72/100
- Event
- Analyst action
- Published
- 30 Jun 2026 13:09
- Source
- Moomoo
$HTFL stock is down 13% today. Here's what we see in our data.
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 30 Jun 2026 07:00
- Source
- Quiver Quantitative
HeartFlow, Inc.(NasdaqGS: HTFL) dropped from Russell Small Cap Comp Value Benchmark
HeartFlow, Inc. (NasdaqGS: HTFL) has been removed from the Russell Small Cap Comp Value Benchmark, as well as the Russell 3000E Value, Russell 3000 Value, Russell 2500 Value, and Russell 2000 Value Benchmarks. This news comes shortly after the company reported Q1 2026 earnings wi
- Tone
- Negative 37/100
- Event
- Earnings
- Published
- 29 Jun 2026 18:13
- Source
- www.marketscreener.com
HeartFlow: Finding Its Flow, Outpacing Guidance (NASDAQ:HTFL)
HeartFlow (HTFL) reported strong Q1 results with 41% revenue growth and gross margins over 80%, exceeding previous guidance. The company raised its full-year sales outlook to $228–$232 million, suggesting conservative management despite continued account growth and market share g
- Tone
- Positive 65/100
- Event
- Earnings
- Published
- 29 Jun 2026 15:04
- Source
- Seeking Alpha
HTFL Forecast — Price Target — Prediction for 2027
This article provides a forecast and price target for Heartflow, Inc. (HTFL) stock based on analyst opinions, with a maximum estimate of $40.00 and a minimum of $35.00. It also covers the company's recent stock performance, financial metrics like revenue and earnings, market capi
- Tone
- Positive 63/100
- Event
- Earnings
- Published
- 29 Jun 2026 12:40
- Source
- TradingView
Form 4 Heartflow Inc For: 26 June By Investing.com
This article from Investing.com announces a Form 4 filing for Heartflow Inc. on June 26th. It briefly mentions the stock symbol HTFL and its performance on that day. The article is very concise and primarily serves as a notification of the filing.
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 28 Jun 2026 00:10
- Source
- Investing.com Nigeria
Heartflow CEO John Farquhar sells $1.36m of HTFL stock
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 26 Jun 2026 07:00
- Source
- Investing.com
HeartFlow vs. NovoCure: Which Emerging Healthcare Stock Is a Better Buy in 2026?
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 24 Jun 2026 07:00
- Source
- The Motley Fool
BrightSpring Health Services (BTSG) Stock Analysis: Exploring Growth Amidst Strong Revenue Surge
- Tone
- Positive 95/100
- Event
- Earnings
- Published
- 01 Jun 2026 07:00
- Source
- DirectorsTalk Interviews